JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus

Key Takeaways J&J said nipocalimab met the primary endpoint in the phase IIb JASMINE study in SLE.The study also hit key secondary and exploratory endpoints, including signals for steroid sparing.Nipocalimab is approved under the brand name Imaavy for treating generalized myasthenia gravis.Johnson & Johnson (JNJ) announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for treating adult patients with systemic lupus erythematosus (SLE), has met the primary endpoint.Th ...